Business Context and Reporting Period
Company: Inhibrx Biosciences, Inc. (INBX)
Filing Type: Form 8-K (Current Report)
Date of Report: October 23, 2025
Primary Event: Announcement of positive topline results from the registrational ChonDRAgon trial for ozekibart (INBRX-109) in chondrosarcoma, alongside updates on colorectal cancer and Ewing sarcoma expansion cohorts.
Key Financial Metrics
This filing is a Current Report on Form 8-K focused on clinical trial results and regulatory milestones. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metric.
Material Changes and Clinical Results
Chondrosarcoma (ChonDRAgon Study)
- Primary Endpoint: Met with statistical significance (P<0.0001).
- Progression-Free Survival (PFS): Median PFS increased to 5.52 months for ozekibart versus 2.66 months for placebo (52% reduction in risk of progression or death; HR 0.479).
- Disease Control Rate: 54% for ozekibart vs. 27.5% for placebo.
- Significance: First investigational therapy to demonstrate significant PFS benefit in a randomized trial for chondrosarcoma.
- Safety: Generally well tolerated. Hepatotoxicity risk was mitigated through patient exclusion and monitoring; incidence was 11.8% (ozekibart) vs. 4.5% (placebo), mostly Grade 1 or 2.
Colorectal Cancer (CRC)
- Regimen: Ozekibart in combination with FOLFIRI.
- Population: Heavily pretreated (80% prior irinotecan); 70% fourth-line, 30% third-line therapy.
- Efficacy (26 evaluable patients): 23% Overall Response Rate (ORR) and 92% Disease Control Rate.
- Comparison: Outcomes exceed standard of care expectations (typical response 5-6%).
Ewing Sarcoma
- Regimen: Ozekibart in combination with irinotecan and temozolomide (IRI/TMZ).
- Population: Relapsed/refractory; majority third or fourth-line.
- Efficacy (25 evaluable patients): 64% ORR and 92% Disease Control Rate.
- Comparison: Significantly higher than standard IRI/TMZ response rates (15-30%).
Guidance, Outlook, and Risks
Regulatory Outlook
Inhibrx plans to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) in the second quarter of 2026.
Management Commentary
Management highlighted that ozekibart is the first therapy to show significant PFS benefit in chondrosarcoma. The safety profile is manageable, with hepatotoxicity risks effectively mitigated. Detailed results will be presented at the Connective Tissue Oncology Society (CTOS) Annual Meeting on November 14, 2025.
Risks and Contingencies
- Data Finality: Topline data may not reflect final results and remain subject to audit.
- Clinical Development: Risks regarding trial initiation, timing, enrollment, and results.
- Regulatory: No guarantee of accelerated pathways, orphan drug exclusivity benefits, or successful approval.
- Commercialization: Uncertainty regarding pricing, coverage, and reimbursement if approved.
Investor Verification Checklist
- Verify the final data readout at the CTOS Annual Meeting on November 14, 2025, to confirm topline results.
- Monitor the timeline for the planned BLA submission in Q2 2026.
- Review the safety data regarding hepatotoxicity in the full clinical study report.
- Assess the enrollment progress of the CRC and Ewing sarcoma expansion cohorts.
- Check subsequent filings for any updates on the company's cash position and burn rate, as this 8-K does not contain financial data.